Gyre Therapeutics (NASDAQ:GYRE) Posts Earnings Results

Gyre Therapeutics (NASDAQ:GYRE) posted its earnings results on Friday, August 7th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06), FiscalAI reports. Gyre Therapeutics had a negative return on equity of 6.57% and a negative net margin of 15.47%.The firm had revenue of $29.11 million for the quarter, compared to analysts’ expectations of $26.49 million.

Gyre Therapeutics Stock Down 0.3%

GYRE stock opened at $6.57 on Tuesday. The business has a 50 day moving average of $6.48 and a 200 day moving average of $6.93. The firm has a market cap of $732.62 million, a PE ratio of -31.29 and a beta of 1.92. Gyre Therapeutics has a twelve month low of $5.44 and a twelve month high of $9.42.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Zacks Research lowered Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, August 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gyre Therapeutics in a research report on Friday, August 7th. Finally, Wall Street Zen lowered shares of Gyre Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. One equities research analyst has rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Reduce” and a consensus target price of $16.00.

Institutional Investors Weigh In On Gyre Therapeutics

Institutional investors have recently modified their holdings of the stock. Bank of America Corp DE raised its position in shares of Gyre Therapeutics by 28.8% in the 2nd quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock worth $46,000 after purchasing an additional 1,402 shares during the last quarter. JPMorgan Chase & Co. grew its position in Gyre Therapeutics by 84.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock valued at $47,000 after purchasing an additional 2,961 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Gyre Therapeutics by 77.8% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock valued at $54,000 after purchasing an additional 3,244 shares during the last quarter. Dimensional Fund Advisors LP bought a new stake in Gyre Therapeutics during the 4th quarter valued at about $77,000. Finally, Wells Fargo & Company MN increased its stake in Gyre Therapeutics by 132.4% during the 4th quarter. Wells Fargo & Company MN now owns 12,919 shares of the company’s stock valued at $91,000 after purchasing an additional 7,361 shares in the last quarter. 23.99% of the stock is owned by hedge funds and other institutional investors.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.